The study included seven patients with ALK-positive stage II-III NSCLC who received two cycles (28 days per cycle) of ceritinib induction therapy followed by surgery, with a 57% MPR and 2 cases achieving pCR (29%). This evidence concerns the gene ALK and non-small cell lung carcinoma.